A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer
NCT04702737
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class
Conditions
Neuroendocrine Prostate Cancer
Interventions
DRUG:
Tarlatamab
Sponsor
Amgen